Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1349492 | 0.81 | ERN1 (0.39) | ERN1ALDH1A1TSHRSMN1; SMN2GRIA1 | |
| SCHEMBL4746714 | 0.81 | ERN1 (0.39) | ERN1ALDH1A1TSHRSMN1; SMN2GRIA1 | |
| SCHEMBL29955919 | 0.81 | ERN1 (0.39) | ERN1ALDH1A1TSHRSMN1; SMN2GRIA1 | |
| SCHEMBL295466 | 0.77 | ERN1 (0.43) | ERN1TDP1CES2CES1 | |
| SCHEMBL2485696 | 0.76 | — | — | |
| SCHEMBL14033478 | 0.74 | ERN1 (0.52) | ERN1ALDH1A1TSHRSMN1; SMN2KDM4E | |
| SCHEMBL15085652 | 0.74 | ALDH1A1 (0.38) | ERN1ALDH1A1TSHRSMN1; SMN2GRIA1 | |
| SCHEMBL12450080 | 0.74 | ERN1 (0.52) | ERN1ALDH1A1TSHRSMN1; SMN2KDM4E | |
| SCHEMBL4293546 | 0.74 | ERN1 (0.42) | ERN1ALDH1A1TSHRTDP1PTGS1 | |
| SCHEMBL29953689 | 0.74 | ERN1 (0.52) | ERN1ALDH1A1TSHRSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1310510-A2 | Topologically segregated, encoded solid phase libraries | SELECTIDE CORPORATION (US) | 2003-05-14 | — | — | EP | claimed |
| CN-117623897-A | Preparation method of o-trifluoromethyl benzoic acid | 浙江巍华新材料股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11578071-B2 | Preparation of pyrazolo[3,4-B]pyridines as antimalarials | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| CN-114436810-A | Method for preparing o-trifluoromethylbenzoic acid | 宁夏忠同生物科技有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-101168496-A | Method for preparing 2-(Trifluoromethyl)benzaldehyde | GAOYOU GUANGMING CHEMICAL FACT (CN) | 2008-04-30 | — | — | CN | disclosed |
| EP-1040097-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| US-20010036950-A1 | Potassium channel openers | CARROLL WILLIAM A (US) | 2001-11-01 | — | — | US | disclosed |
| US-6265417-B1 | MUSCLE RELAXANTS | ABBOTT LABORATORIES | 2001-07-24 | — | — | US | disclosed |
| WO-2000053313-A2 | LANTHANIDE CATALYSTS FOR SYNTHESIS OF COMPOUNDS AND COMBINATORIAL LIBRARIES | ARQULE, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-1998010286-A1 | METHODS FOR PROCESSING CHEMICAL COMPOUNDS HAVING REACTIVE FUNCTIONAL GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1998-03-12 | — | — | WO | disclosed |
| EP-0371492-A2 | Process for the preparation of 1,4-dihydropyridine derivatives | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1990-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578071-B2 | Preparation of pyrazolo[3,4-B]pyridines as antimalarials | PNPO, NOX3, G6PD | ERN1 2932/4885ALDH1A1 2771/4885TSHR 3974/4885 |
| US-20010036950-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | ERN1 1037/4885ALDH1A1 709/4885TSHR 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.